John Ripple founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development, and capital fundraising activities.
He previously served as CEO of 5 venture-backed biotech companies, including Exonics Therapeutics (acquired by Vertex), Virdante Pharmaceuticals (acquired by Momenta), and Syntonix Pharmaceuticals (acquired by Biogen).
Mr. Ripple also held positions in business development, entrepreneur-in-residence, medical device marketing, and management consulting. He started his career as an aerospace engineer at NASA. He currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), on the Board of Directors and Treasurer of the Children’s Melanoma Prevention Foundation, and as an advisor to the MIT Deshpande Center for Technological Innovation.
Mr. Ripple received a BS in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.